News Release _rtf_ 61 kb_ - Bayer CropScience - Bayer CropScience

Document Sample
News Release _rtf_ 61 kb_ - Bayer CropScience - Bayer CropScience Powered By Docstoc
					Dr. Gunnar Riemann to head Environmental Science Business Unit of Bayer CropScience
Monheim, September 18, 2009 – Dr. Gunnar Riemann, currently Head of Bayer HealthCare Bayer Schering Pharma Business Units will become new Head of the Environmental Science Business Unit of Bayer CropScience. He succeeds Dr. Pascal Housset, who will end his duties as Head of the Business Unit Environmental Science within Bayer CropScience and Member of the Bayer CropScience Executive Committee effective December 4, 2009. In his new function, Dr. Riemann will become a Member of the Bayer CropScience Executive Committee. Bayer CropScience´s Business Operations unit Environmental Science offers a wide range of plant and lawn care products for the garden and household to private customers and for professional users in the green industry. The unit provides solutions for the control of termites, crawling and flying insects, rats and mice in and around domestic and industrial premises. Through its Environmental Science Business Group, Bayer CropScience also offers a range of products in the control of insects and others pests which act as vectors and are responsible for the transmission of numerous diseases such as malaria, sleeping sickness, chagas, yellow fever or dengue. Gunnar Riemann was born in Hameln, Germany, on October 26, 1958. He studied pharmacy at Braunschweig Technical University and was awarded a Ph.D. in biochemistry for a doctoral thesis written at the German Research Center for Biotechnology. Dr. Riemann started his career with Bayer in 1986 at the Health Care Sector's Institute for Pharmaceutical Technology in Leverkusen, Germany. He was manager of a pharmaceuticals production plant from 1987 to 1991. He then headed OTC product development at the Bayer subsidiary Miles Inc., Elkhart, Illinois until 1994. Dr. Riemann was subsequently Head of the Household Products Business Unit in the Consumer Care Business Group in Leverkusen. In 1996 he was appointed Regional - 1/2 -

Director Asia/South America. From 1999 to September 2001 Dr. Riemann was responsible for the Consumer Care division's business in Europe. He was subsequently appointed Head of the Biological Products Business Group, headquartered in Research Triangle Park, North Carolina. From January 2004 to March 2006 he was Head of the Animal Health Division at Bayer HealthCare. Dr. Riemann subsequently took charge of the Pharma Devision at Bayer HealthCare and, following the acquisition of Schering, became a Member of the Board of Management of Bayer Schering Pharma AG. About Bayer CropScience Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of about EUR 6.4 billion (2008), is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of more than 18,000 and is represented in more than 120 countries. This and further news is available at: Note to editors: A photograph of Dr. Gunnar Riemann is available at Contact: Utz Klages, phone: +49 2173 38-3125 E-mail: Find more information at kgs (2009-0332E)
Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

- 2/2 -

Shared By: